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This work reports the synthesis of boronated chitosan by reacting it with 4-
carboxyphenylboronic acid to improve its mucoadhesive properties. Three products with 
differing extent of boronate conjugation were synthesised and characterised using 1H NMR, FT-
IR and UV-Vis spectroscopy and the potential of these polymers to extend the residence time of 
loaded model drug in the bladder was investigated. 1H NMR and ninhydrin test were used to 
evaluate the extent of chitosan modification. Mucoadhesive properties were evaluated using ex 
vivo flow-through technique on porcine bladder mucosal tissue combined with fluorescent 
microscopy, where fluorescein sodium was used as a model drug. The mucoadhesive properties 
of these polymers on porcine bladder mucosa were also studied using tensile test. There was 
good correlation in the mucoadhesive profiles of the polymers using the flow through and 
tensile techniques. The degree of chitosan modification had a remarkable influence on their 
mucoadhesive behaviour and greater mucoadhesion was observed with increased degree of 
boronation. These chitosan derivatives have the potential as intravesical drug delivery systems 
to improve bladder therapy. 
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1. Introduction 
Bladder cancer is one of the frequent causes of tumour-associated mortality worldwide and the 
overall survival tendency for the advanced stage of the disease is only about a year despite the 
fact that urothelial cancerous tissues respond well to conventional chemotherapeutic agents.1–
3The local bioavailability and residence time of formulations delivered to the bladder is often 
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reduced as drugs are diluted or washed out of the bladder due to urine filling and excretion. 
Thus there is a need to develop better mucoadhesive delivery systems that are resistant to urine 
wash out, thereby prolonging duration of drug action and preventing disease progression.  
Chitosan is a biopolymer with well-established biodegradable, biocompatible and 
mucoadhesive properties.4–6 It is a polysaccharide consisting of acetylated and deacetylated 
glucosamine units, with the deacetylated segment that can be modified to prepare 
mucoadhesive derivatives such as chitosan-cysteine,7 chitosan-thioglycolic acid,8 chitosan-4-
thio-butyl-amidine,9 chitosan-glutathione,10 chitosan-N-acetylcysteine conjugates,11 chitosan-
graft-6-mercaptonicotinic acid12 and methacrylated chitosan.13 
One of the constituents of mucosal membranes are mucin oligosaccharides, which have sialic 
acid groups that are overexpressed in malignant tissues and organs such as the bladder.14 So, 
sialic acid moieties have been explored as therapeutic targets by conjugating polymeric drug 
carriers with phenylboronic acid groups which bind favourably with sialic acid groups to form 
reversible covalent complexes,15 thereby facilitating enhanced mucoadhesion and cellular 
uptake of their therapeutic payload.  
Phenylboronic acid decorated polymers have been explored for the delivery of drugs and 
biotherapeutics because they are biocompatible, mucoadhesive, can form stable colloidal 
systems and have tumour-targeting abilities.16–18 Transmucosal routes that have been explored 
include ocular,19–21 nasal22 and vaginal.23 Due to their responsiveness to glucose level, it makes 
them valuable for glucose detection18,24,25 and as glucose sensitive sustained insulin release 
system.26 They have also been explored for cancer targeting27–30 and gene delivery31,32 due to 
their favourable interaction with sialic acid moieties.  
Liu et al demonstrated that cyclosporine loaded phenylboronic acid conjugated polymeric 
nanoparticles reduced ocular drug clearance. The boronated nanoparticles displayed good drug 
encapsulation efficiency (13.7 % w/w), reduced inflammation after topical application to dry-
eye induced mice, and sustained drug release of up to 5 days showing their potential in reducing 
dosing interval and improving ocular drug bioavailability.20  
Recently, in vivo studies using H22 lung metastasis tumour-bearing mice showed that 
doxorubicin loaded boronate modified chitosan nanoparticles exhibit greater antitumour 
activity than carboxymethyl chitosan nanoparticles.33 3- and 4-carboxyphenylboronic acid 
modified chitosan nanoparticles were shown to exhibit superior doxorubicin loading, active 
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tumor targeting, cellular internalisation and target site retention, relative to unmodified 
nanoparticles.33,34 
Asantewaa et al studied the correlation between the physicochemical features of various 
boronic-acid-chitosan conjugates to their glucose adsorption properties.35 However, to our 
knowledge, there are no studies investigating how the physicochemical properties of different 
boronated chitosan affect urothelial mucoadhesiveness as a potential intravesical dosage form 
for bladder cancer treatment. Thus there is a critical need to establish whether boronated 
chitosan has sufficient interaction with the urothelial mucosa that is constantly in contact with 
urine, to prolong drug residence time in the bladder. 
In this work, we synthesised boronate-conjugated chitosan derivatives by reaction of chitosan 
with 4-carboxyphenylboronic acid using EDC and NHS as coupling agents, characterised the 
resultant products in terms of their physicochemical properties and evaluated in vitro adhesion 
to porcine urinary bladder mucosa to establish their intravesical drug delivery potential.  
2. Materials and Methods 
2.1. Materials  
Chitosan (high molecular weight grade, 370 kDa; degree of acetylation extent 29.3 ± 2.5 %), 
ninhydrin, trifluoroacetic acid, FITC-dextran (3-5 kDa), dextran 5 kDa, deuterium oxide, urea, 
uric acid, magnesium sulphate heptahydrate, sodium hydrogen phosphate, creatinine, sodium 
bicarbonate, sodium sulphate, disodium oxalate and trisodium citrate were all purchased from 
Sigma-Aldrich, UK. 4-carboxyphenylboronic acid (4-CPBA), N-3(dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), dimethyl sulfoxide 
(DMSO), disodium hydrogen phosphate, sodium chloride, potassium chloride, ammonium 
chloride and calcium chloride dihydrate  were all purchased from Fisher Scientific, UK. Dialysis 
membrane with molecular weight cut off 12-14 kDa was obtained from Medicell International, 
UK. All chemical reagents were used as received without further purification. Freshly excised 
porcine urinary bladders were procured from PC Turner Abattoir (Farnborough, Hampshire, UK).  
2.2. Synthesis of boronated chitosan 
Three types of boronated chitosan were synthesised by varying the molar amount of 4-CPBA 
(Table 1) using a published method with modification.34 
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Briefly, 1.5% w/v chitosan solution (100 mL) was prepared in 4% v/v acetic acid for 12 h at room 
temperature for complete polymer dissolution. According to Table 1, the required amounts of 
4-CPBA, EDC and NHS were dissolved in predetermined amounts of DMSO, stirred under dark 
conditions at room temperature for 30 min. The 4-CPBA/NHS/EDC mixtures were then added 
slowly to chitosan solution and stirred for another 24 h at room temperature, in the dark. The 
products were redispersed in deionised water, purified by dialysis in the dark (MWCO 12-14 kDa 
membrane) against 4.5 L of 7 mM HCl for 24 h (three changes) followed by dialysis against 4.5 L 
deionised water for 2 days (6 changes) to remove unreacted 4-CPBA. The products were freeze-
dried using Heto PowerDry LL3000 Freeze Dryer (Thermo Scientific, UK). 
Table 1  
Materials used for the synthesis of boronated chitosan, with low (LBCH), medium (MBCHI) and high 
(HBCHI) degrees of modification. 
Parameters LBCHI MBCHI HBCHI 
Chitosan (CHI) concentration (% w/v) 1.5 1.5 1.5 
4-carboxyphenyl boronic acid (4-CPBA, g) 0.28  0.56  1.11  
N-3(dimethylaminopropyl)-N-ethylcarbodiimide 
hydrochloride (EDC, g) 
0.39  0.77  1.54  
N-hydroxysuccinimide (NHS, g) 0.23  0.47 0.93 
DMSO for 4-CPBA, EDC & NHS dissolution (mL) 5 10 20 
Moles of 4-CPBA per unit mole CHI 0.20 0.39 0.79 
2.3. Characterisation of boronated chitosan 
2.3.1. 1H NMR spectroscopy 
Solutions of CHI, LBCHI MBCHI, and HBCHI (0.6 %w/v) were prepared in D2O acidified with 30 µL 
trifluoroacetic acid and allowed to be dissolved overnight at room temperature. The 1H NMR 
spectra were recorded using 400 MHz Ultrashield Plus™ B-ACS 60 spectrometer (Bruker, UK). 
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Fig. 1. Reaction scheme for the synthesis of boronated chitosan: CHI is the parent chitosan and LBCHI, 
MBCHI, and HBCHI are chitosans with low, medium, and high degrees of boronation, respectively; a 
(deacetylated), b (acetylated), and c (boronated) segments of chitosan repeating units. 
2.3.2. Quantification of the extent of chemical modification 
The quantity of boronate groups conjugated to chitosan was calculated using previously 
published method with slight modification.36 Briefly, 2 %w/v solution of ninhydrin in DMSO was 
prepared by stirring for 12 h, protected from light at room temperature. Unmodified and 
modified chitosan solutions (0.05 – 0.5 %w/v) were prepared by dissolving in 0.1 M acetic acid, 
stirred for 12 h under dark conditions at room temperature. 5mL of ninhydrin solution and 1.25 
mL of 4M phosphate buffer (pH 5.4±0.2) were mixed with 0.5 mL polymer solution. The resultant 
mixtures were incubated in a water bath at 85oC shaken at 60 rpm for 30 min. The degree of 
chitosan amine substitution was determined using microplate spectrophotometer at 500 nm 
(Epoch, BioTek Instruments Inc., UK). Mixture of ninhydrin solution and phosphate buffer 
solution (4M, pH 5.4) (4:1) served as the blank control. 
 
 
2.3.3. Fourier Transform-Infrared spectroscopy (FT-IR) 
Solid samples of modified and unmodified chitosan were scanned from 4,000 to 600 cm-1, 
resolution of 4 cm-1 to identify characteristic functional groups in both chitosan and the 
boronate moieties that suggested that boronation was successful. Data was processed based 
on the average of sixteen scans per spectrum generated by FT-IR spectrometer (PerkinElmer 
Spectrum 100, Thermo Scientific, UK). 
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2.3.4. Turbidimetric analysis 
The influence of pH on the turbidity of polymer samples was evaluated based on a method 
reported by Sogias et al. (2010) with slight modification.37 Briefly, polymer solutions (0.1 %w/v, 
pH 3) were prepared in 0.1M acetic acid at room temperature. NaOH solution (0.1 molL-1) was 
added to increase the pH stepwise from 3 to 9 and 0.1 molL-1 HCl was used to adjust the pH of 
the samples if necessary. The turbidity values of polymer dispersions were measured at 400 nm 
using UV-Vis spectrophotometer (Jenway 7315, Bibby Scientific, UK).  
2.3.5. X-ray diffraction analysis 
In order to investigate the influence of boronation on the crystallinity of chitosan, solid forms of 
the polymers were studied using an earlier reported method.13 Briefly, solid samples of CHI, 
LBCHI, MBCHI, and HBCHI were loaded into a capillary tube sealed with wax to avoid loss of 
sample and placed onto the goniometer under a microscope to be analysed with a wide-angle 
powder D8 Advance diffractometer/LYNXEYE XE detector (Bruker, UK). Samples were scanned 
at diffraction ranges from 5 to 65oC with a scan step of 0.02o, producing distinctive 
diffractograms at the rate of 2.5 scans min-1. 
2.4. Ex vivo porcine mucoadhesion studies 
2.4.1. Preparation of polymer / fluorescein sodium mixtures and artificial urine solutions 
The solutions/dispersions of CHI, LBCHI, MBCHI and HBCHI were prepared by dissolving the 
polymers in 0.1 M acetic acid and stirred overnight in dark conditions at room temperature. 
Resultant polymer solutions/dispersions were mixed with 0.1 %w/v fluorescein sodium to yield 
final polymer concentration of 0.4 %w/v (FS/CHI, FS/LBCHI, FS/MBCHI and FS/HBCHI, 
respectively). FITC-dextran 0.4 %w/v in deionised water served as negative control. 
Chutipongtanate and Thongboonkerd (2010) method38 was used to prepare artificial urine. 
Briefly, urea (24.27 g), uric acid (0.34 g), magnesium sulphate heptahydrate (1.00 g), sodium 
hydrogen phosphate (1.00 g), disodium hydrogen phosphate (0.11 g), creatinine (0.90 g), 
sodium bicarbonate (0.34 g), sodium sulphate (2.58 g), disodium oxalate (0.03 g), trisodium 
citrate (2.97 g), sodium chloride (6.34 g), potassium chloride (4.50 g), ammonium chloride (1.61 
g), and calcium chloride dihydrate (0.89 g) were dissolved in 2 L ultrapure water (18.2 MΩ) for 
3 h at room temperature. The resultant artificial urine had a final pH of 6.2±0.2. 
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2.4.2. Retention on porcine urinary bladder mucosa 
Fluorescence microscopy (MZ10F microscope, Leica Microsystems, UK), coupled to an “ET GFP” 
filter camera (Zeiss Imager A1/AxioCam MRm camera, 1296 x 966 pixels, 0.8 x magnification) 
was used to investigate the mucosal retention of model drug fluorescein sodium in the presence 
of the polymeric carriers based on a slightly modified protocol developed in-house.39 Freshly 
excised porcine urinary bladders were stored on ice until use and used within 24 h of 
procurement. The mucosal side of the bladder tissue was prevented from any possible damage 
during excision of the studied mucosal section about 1.5 x 2.5 cm and rinsed with artificial urine 
solution (~ 3 mL) prior to blank tissue imaging. The bladder tissue was placed on a glass slide 
and maintained in an incubator at 37oC during urine wash-out. The following exposure times 
were used: FITC-dextran (80 ms), FS/CHI (211 ms), FS/LBCHI, FS/MBCHI and FS/HBCHI (86 ms). 
Microscopic images of the tissues were taken before and after sample application (50μL) as well 
as after each of the five washing cycles with 10 mL artificial urine/cycle at 2 mL/min. The studies 
were carried out in triplicates. Image J software (National Institute of Health, USA) was used to 
analyse the microscopic images, generating average fluorescence values as a function of urine 
volume used for the wash-out. Fluorescence intensity values were normalised against the blank 
tissue control. The WO50 values (volume of artificial urine required to wash-out 50 % of the 
applied fluorescence sodium/polymer mixture) were determined based on the polynomial fit of 
the percent mucosal fluorescence retention versus artificial urine volume graphs (Fig. S1, 
Supplementary information). 
2.5. Tensile method 
The TA-XT Plus Texture Analyser (Stable Micro Systems Ltd, UK) coupled to a 5 kg load cell was 
used as an additional technique to study the mucoadhesive properties of the polymer samples. 
Blank chitosan solutions (0.4 %w/v in 0.1 M acetic acid solution) served as the positive control, 
while the negative control was dextran solution (0.4 %w/v in water). Porcine bladder tissues 
were secured at the base of a cylindrical container. The vessel bottom had a circular cut-out 
region (20 mm diameter) exposing the mucosal surface of the bladder tissue. This container was 
screwed onto the probe of the texture analyser through a hole drilled on the lid of the container. 
Another bladder tissue was placed on a petridish and coupled onto the lower platform of the 
texture analyser, exposing the mucosal surface (20 mm diameter) of another bladder tissue. The 
tests were performed using an earlier reported equipment settings40 with slight modification: 
pre-speed test 1.0 mm/s; test speed 0.1 mm/s; post-test speed 0.1 mm/s; applied force 0.05 N; 
contact time 120.0 s; trigger type auto; trigger force 0.1 N; and return distance of 10.0 mm. 
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Bladder tissues were maintained in an incubator at 37oC for 5 min prior to the study. CHI, 
dextran, LBCHI, MBCHI and HBCHI samples (0.4 mL) were applied onto the exposed area of the 
bladder tissue secured onto the lower platform of the texture analyser. The probe was then 
lowered such that the upper blank bladder tissue comes in contact with the formulation applied 
onto the bladder tissue secured on the lower platform for 2 min. The Texture Analyser software 
(T.A. Exponent) was used to record the area under the force versus distance curves (work of 
adhesion) as well as the force of adhesion/adhesive strength which is the maximum force 
needed to detach tissue from the polymer solutions/dispersions.40,41 
2.6. Statistical analysis 
All experimental data were collected in triplicates and data expressed as mean ± standard 
deviation. Data were compared using t-test and one-way ANOVA/post-hoc Bonferroni test with 
GraphPad Prism 5.04 (GraphPad Software Inc., San Diego, California), with p < 0.05 depicting 
significant statistical difference between data sets. 
3. Results and discussion 
The potential for chitosan as material for drug delivery and tissue engineering cannot be 
overemphasised due to its physical and biological properties such as biocompatibility, 
mucoadhesiveness and permeation enhancing properties.5,42–44 Chemical modification of 
chitosan with boronate groups may impact on its urothelial mucoadhesiveness. The 
biocompatible nature of boronate modified chitosan nanoparticles has been previously 
established in mouse and mammalian cells.33,34 Over 90% of human bone marrow 
neuroblastoma SH-SY5Y cells, human liver cancer HepG2 cells and mouse liver cancer H22 cells 
remained viable after incubation with chitosan and boronated chitosan based nanoparticles for 
48h.34 Also, boronated dextran based formulations were tested on healthy rabbit eyes and did 
not trigger any inflammatory response acutely (1 week) and chronically (12 weeks).20 These 
studies suggested that boronated drug carriers are safe. Consequently, cytotoxicity testing was 
not carried out for the studied boronated chitosan. Moreover, several in vitro and in vivo studies 
have already established the safety of phenylboronate molecules.17,20,45  
3.1. Synthesis of boronated chitosan derivatives and physical properties 
Three types of boronated chitosan were synthesised (Table 1) using EDC/NHS chemistry which 
is an efficient synthetic method for covalent amide bond formation.46 The yields of LBCHI, 
MBCHI, and HBCHI were 61%, 43%, and 33%, respectively and all materials were off white colour 
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(Table 2). The product yield decreased as the extent of chitosan modification increased. This 
finding correlates well with our previous studies where chitosan with low extent of 
methacrylation produced a greater yield (62%) than sample with a high extent of methacrylation 
(24%).13 The potential reacetylation of chitosan with acetic acid under the conditions of the 
reaction does not happen as it is seen from the analysis of acetylation degrees of all products, 
which do not change significantly.  
Table 2  
Yield and degrees of boronation (using 1H NMR spectroscopy and ninhydrin test) and acetylation (using 
1H NMR spectroscopy) of LBCHI, MBCHI, and HBCHI  
Parameter Chitosan LBCHI MBCHI HBCHI 
Yield (%) n/a 61 43 33 
Boronation extent 
(%) 
1H NMR 
 
n/a 
 
 
3.9 ± 0.3 
 
5.5 ± 0.1 
 
16.5 ± 0.2 
 
Ninhydrin test n/a 4.4 ± 1.8 
 
7.4 ± 1.2 
 
10.7 ± 2.2 
 
Acetylation (%) 29.3±2.5 
 
26.6±1.0 
 
29.4±0.9 31.8±1.5 
 
 
According to the 1H NMR spectra (Fig. 2), the characteristic peaks of chitosan were evident at 
2.0 ppm (-CH3 from the acetylated segment of chitosan) as well as 3.1-3.8 ppm (protons from 
the glucosamine ring). With the boronated chitosan, additional peaks were evident at 7.8-8 ppm 
representative of the phenyl ring protons from the boronate moiety, confirming the successful 
conjugation of phenylboronate groups to chitosan. Also, the peaks at 2.7-2.8 ppm for the 
boronated chitosan are the result of the quartet methyne protons of the boronic acid. These 
spectral data are in good agreement with that reported by Zhang et al.14 
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Fig. 2. 1H NMR spectra of CHI (1), LBCHI (2), MBCHI (3), and HBCHI (4), recorded in D2O acidified with 1% 
trifluoroacetic acid. Methyl protons from the acetylated part of chitosan observed at 2.0 ppm (i), methyne 
protons from the boronate moiety were evident at 2.7 - 2.8 ppm; (ii) H2-H6 protons of CHI were detected 
at 3.0-4.0 ppm (iii & iv) and benzene ring of the boronate groups detected around 7.8 and 8.0 ppm (v & 
vi). 
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Their degree of boronation was calculated from the ratio of mean intensity of the proton peaks 
of the boronate moieties (δ = 7.8-8.0 ppm) relative to that of the chitosan glucosamine protons 
(δ = 3.0-4.0 ppm). 
𝐵𝑜𝑟𝑜𝑛𝑎𝑡𝑖𝑜𝑛 (%) =
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑏𝑜𝑟𝑜𝑛𝑎𝑡𝑒 𝑝𝑟𝑜𝑡𝑜𝑛𝑠 𝑎𝑡 7.8 & 8.0 𝑝𝑝𝑚 /2
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 𝐻2−𝐻6  𝑝𝑟𝑜𝑡𝑜𝑛𝑠 /6
100%                (1) 
Based on 1H NMR data analysis (Fig. S1), a two-fold increase in the ratio of 4-CPBA per unit mole 
of chitosan used for LBCHI to generate MBCHI (Table 1) did not show a doubling of boronate 
conjugation (3.9% vs 5.5%, respectively) despite doubling the amount of boronate groups 
available to conjugate with the chitosan primary amino group. However, a 3-fold increase in the 
degree of boronation occurred when doubling the quantity of 4-CPBA in HBCHI against MBCHI 
with boronation of 5.5% and 16.5%, respectively. This finding may be due to a critical amount 
of 4-CPBA required to conjugate boronate groups to chitosan amine groups significantly.  
3.2. Calculation of boronation extent using ninhydrin test 
The ninhydrin test was used as an additional means of quantifying the degree of substitution of 
chitosan amine groups with boronate moieties. The principle of detection is based on the fact 
that ninhydrin reacts with the unmodified amine groups of chitosan to form a coloured product 
measurable by UV spectroscopy.47 The slope of the adsorption versus concentration curve of 
unconjugated chitosan is represented as δCHI, while that of LBCHI, MBCHI, and HBCHI are 
denoted as δBCHI. Boronation percentage can be defined as (1-δBCHI/δCHI)* 100%. 13,36The 
respective boronation extent for LBCHI, MBCHI, and HBCHI were 4.4%, 7.4%, and 10.7% (Table 
2). These values were comparable with that calculated using 1H NMR spectroscopy (3.9%, 5.5%, 
and 16.5%, respectively) and showing the same trend in the degree of boronation with an 
increase in the molar ratio of 4-CPBA used. 
3.3. FT-IR analysis 
FT-IR spectra (Fig. 3) showed pronounced absorption band at 1026-1151 cm-1 indicating the 
amine C-N stretch from chitosan. Since both chitosan and boronate groups exhibit alkyl C-H 
stretch at 2850 and 2930 cm-1, the increase in the intensity of the absorption bands depicts the 
formation of the boronated chitosan. The appearance of the new signal at 1311 cm-1 indicated 
–B(OH)2 groups of the boronic acid segment and peaks evident at 713 and 1533 cm-1 
represented para-substituted benzene ring. The prominent absorption peak at 1636 cm-1 in 
LBCHI, MBCHI and HBCHI confirmed the successful grafting of phenylboronate groups onto 
chitosan. This finding is in good agreement with the FT-IR spectra chitosan-boronate conjugate 
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reported in earlier studies 14 where –B(OH)2 groups were evident at 1333 cm-1; aromatic C-H 
bending bands were observed at 713 cm-1 while that of the benzene ring appeared at 1546 cm-
1. Also, the absorption peak confirming chitosan boronation (1636 cm-1) is comparable to that 
of the chitosan-boronate conjugate earlier reported (1643 cm-1). The FT-IR spectra of LBCHI, 
MBCHI and HBCHI are comparable but vary in terms of the spectral intensity, which is dictated 
by their degree of boronation.  
 
Fig. 3. FT-IR spectra of chitosan and boronated chitosan with distinct peak at 1311 cm-1 indicative of –
B(OH)2 groups; absorption bands at 713 and 1533 cm-1 depicted p-substituted benzene and absorption 
band confirming –NH-CO- linkage between chitosan and boronate groups evident at 1636 cm-1. 
3.4. Turbidimetric analysis 
The typical pH of the bladder environment is between 6 and 7. However, various factors such 
as diet and disease states such as bladder cancer can impact urine pH resulting in pH ranges 
from 4.6 to 8.48–50 Moreover, changes in solution turbidity may impact product stability and 
performance. Thus there is a need to develop drug carriers that will withstand possible pH 
changes in the bladder.  
The modified and unmodified chitosan solutions maintained transparency until pH 6.5, where 
further increase in pH resulted in a drastic increase in solution turbidity (Fig. 4). This turbidity-
pH pattern is in good agreement with our earlier reports,13,37 where the unmodified chitosan 
and the chitosan with low extent of methacrylation displayed steep increase in degree of 
turbidity at ≥ pH 6.5 comparable to our boronated chitosans. The influence of boronate 
conjugation on the turbidity of chitosan solution was pronounced at pH ≥ 7, where the 
boronated chitosans displayed a lower turbidity than that of the unmodified chitosan (p < 0.05). 
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This is because at pH ≥ 7 and higher degree of boronate conjugation, the bulky boronate groups 
would disrupt the semi-crystalline nature of chitosan, thereby improving its solubility and 
decreasing the solution turbidity.13,37  There was significant difference in the turbidity values of 
the boronated chitosan at pH 9 (Fig. 4).  
 
Fig. 4. Effect of pH on solution turbidity of unmodified and boronated chitosan (n=3, mean ± standard 
deviation)  
3.5. X-ray diffraction analysis 
Chitosan is a semi-crystalline polymer that displayed two main peaks at diffraction angles of 9.8o 
and 20.5o (Fig. 5). This finding is in good agreement with that of the chitosan peaks we previously 
reported.13,37,51,52 There was reduction in the crystallinity of chitosan after boronation with the 
disappearance and broadening of peaks as well as peaks appearing at a diffraction angle 
different from that of chitosan. The boronated chitosan did not exhibit any peak at a diffraction 
angle of 9.8o. The distinctive broad peaks for LBCHI, MBCHI and HBCHI were evident at 20.5o, 
21.6o and 21.9o, respectively (Fig. 5). This finding is in good agreement with that observed with 
the methacrylated chitosans with loss and broadening of peaks evident at diffraction angles of 
8.3o and 22.4o, respectively.13  
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Fig. 5. X-ray diffractograms of CHI, LBCHI, MBCHI and HBCHI generated at scan angle 5-65o, 2.5 scans·min-
1, scan step of 0.02o, spectra offset for improved clarity. 
3.6. Urine wash-out studies 
Fluorescein sodium (FS), which served as the model drug, was mixed with the unmodified and 
boronated chitosan prior to the mucoadhesion studies. The unmodified chitosan served as the 
mucoadhesive positive control,53 while the negative control was FITC-dextran, with limited 
mucoadhesive property.54 The ex vivo porcine bladder was used to measure the wash-out50 
values of fluorescein sodium in the presence of the unmodified and boronated chitosan. WO50 
is the volume of artificial urine needed to remove 50% of fluorescein from the bladder mucosal 
surface.39 
FITC-dextran displayed the least mucosal retention on the porcine bladder mucosa (WO50 of 7±2 
mL, Fig. 6) from extrapolation as 10 mL of artificial urine was used for each wash-out cycle similar 
to that reported previously.13,39 FITC-dextran was significantly less mucoadhesive than the 
boronated chitosan over the five washing cycles (with 50 mL artificial urine) (p < 0.05). Also, 
unmodified chitosan was significantly more mucoadhesive than FITC-dextran (p < 0.05).  
Typically, cationic polymers like chitosan interact with negatively charged sialic acid groups 
present on urothelial mucosal surfaces via electrostatic interaction. Phenylboronic acid is 
composed of phenyl substituent and two hydroxyl groups attached to boron, which enables it 
to form a complex with the diol groups of sialic acid at physiological pH.15 The presence of 
counter ions in the artificial urine used for the wash-out studies inhibits the favourable 
interaction of chitosan with sialic acid-rich mucosal surfaces. Chitosan conjugation with 
boronate groups (HBCHI) resulted in 3.1-fold increase in their WO50 values. The WO50 values of 
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FS/CHI, FS/LBCHI, FS/MBCHI and FS/HBCHI were 15±4 mL, 23±3 mL, 48±5 mL and 55±2 mL, 
respectively, calculated based on the polynomial fit of the mucosal fluorescence retention 
versus urine volume graph (Fig. S2). Boronated chitosan may interact with mucosal surfaces 
through various mechanisms:22 (i) the phenylboronic acid groups could potentially form 
covalent linkage with sialic acid expressed on cell membranes to form reversible covalent 
complexes55,56, (ii) hydrogen bond formation with mucin glycoproteins possible due to its 
constituent hydroxyl groups43 and (iii) electrostatic interaction between cationic polymer and 
negatively charged sialic acid residues.42,53 Therefore, the greater degree of mucoadhesion as 
seen in HBCHI could be due to the more boronate groups being available to interact with the 
mucosal surface (Fig. 6 and Fig. 7).  
Significant difference in the mucoadhesive behaviour of the parent chitosan and the boronated 
derivatives (LBCHI, MBCHI and HBCHI) can be seen after two urine washing cycles and 
differences remained significant after five washing cycles (p < 0.05). MBCHI and HBCHI were 
significantly more mucoadhesive than LBCHI after the first washing cycle with 10 mL artificial 
urine. On the other hand, the mucoadhesive behaviour of MBCHI and HBCHI was not 
significantly different after 5 washing cycles with 50 mL artificial urine. This finding indicated 
that the urine wash-out resistance of boronated chitosan may become unchanged after a 
certain degree of boronation. Fig. 7 confirmed that FS/CHI and FS/LBCHI displayed comparable 
mucoadhesiveness in terms of their WO50 values (15±4 mL vs 23±3 mL) but that of HBCHI was 
significantly more mucoadhesive than MBCHI, with WO50 values of 48±5 mL and 56±2 mL, 
respectively. Thus, boronation still had a somewhat influence on the mucoadhesiveness of the 
boronated chitosans, which was most prominent after washing out the bladder mucosa with 30 
mL artificial urine. 
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Fig. 6. Ex vivo urine wash-out studies using porcine urinary bladder with fluorescently labelled dextran, 
FS/CHI, FS/LBCHI, FS/MBCHI and FS/HBCHI. (a) Exemplary fluorescent microscopic photos of the urinary 
bladder over 5 washing cycles, scale bar represents 2 mm; (b) Mucosal retention of the model drug 
fluorescein sodium mixed with CHI, LBCHI, MBCHI and HBCHI at different washing cycles; FITC-dextran 
served as negative control and FS/CHI (unmodified chitosan) as positive control. Results presented as 
average ± standard deviation, n = 3, all the studied groups of samples displayed statistically significant 
differences between them (p < 0.05) except those depicted by “ns” implying no significant differences 
between particular groups of samples. 
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It is important to note that the two formulations with better retention (FS/MBCHI and 
FS/HBCHI) show anomalously brighter images and over 100 % mucosal retention values in the 
initial wash with 10 mL. This could be related to positive deviations in the fluorescence intensity 
in this concentration range of sodium fluorescein as reported in Ref.57 However, these 
deviations do not affect the overall result showing greater retention of sodium fluorescein with 
MBCHI and HBCHI formulations.   
 
 
Fig. 7. Urine wash-out50 values of FITC-dextran, CHI, LBCHI, MBCHI and HBCHI. Results presented as 
average ± standard deviation, n = 3; all the studied groups of samples displayed statistically significant 
differences between them (p < 0.05) except those depicted by “ns” implying no significant differences 
between particular groups of samples. 
3.7. Mucoadhesive properties studied using tensile test 
The force of detachment or adhesive strength indicates the force required to overcome the 
adhesive bonds between the drug carrier and bladder mucosa, while the work of adhesion is 
the area under the force-distance curves. 
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Fig. 8. (a) Force of detachment and (b) work of adhesion of dextran, CHI, LBCHI, MBCHI and HBCHI to 
porcine bladder mucosa measured using tensile test. Results presented as mean ± standard deviation, n 
= 3; all the studied groups of samples displayed statistically significant differences between them (p < 
0.05) except those depicted by “ns” implying no significant differences between particular groups of 
samples. 
 Though, dextran and CHI displayed similar force of detachment (Fig. 8), the work of adhesion 
values showed that CHI was statistically more mucoadhesive than dextran. MBCHI and HBCHI 
were significantly more mucoadhesive compared to the unmodified chitosan with the force of 
detachment in increasing order from dextran (0.04±0.01 N) < CHI (0.06±0.01 N) < LBCHI 
(0.08±0.01 N) < MBCHI (0.12±0.01 N) < HBCHI (0.32±0.02 N). CHI vs LBCHI; LBCHI vs MBCHI and 
MBCHI vs HBCHI displayed comparable forces of detachment and work of adhesion values. The 
work of adhesion presented in increasing order: CHI (0.14±0.02 N·mm) <LBCHI (0.16±0.02 
N·mm) < MBCHI 0.2±0.01 N·mm < HBCHI (0.4 N±0.02 N·mm). Overall, the adhesive strength of 
the polymers correlated well with their work of adhesion as MBCHI and HBCHI exhibited greater 
force of detachment and work of adhesion relative to the parent chitosan. Though dextran and 
CHI displayed similar force of detachment, the work of adhesion values showed that CHI was 
statistically more mucoadhesive than dextran. These findings inferred that the 
mucoadhesiveness of the polymers was improved with increased extent of boronation. This is 
in good agreement with the urine-wash-out test data. 
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4. Conclusions 
Chitosan boronation had a profound influence on the mucoadhesiveness of the new polymers 
as their mucoadhesive properties (in terms of wash-out50 profile, force of adhesion/detachment 
and work of adhesion) were greatest for the highly boronated chitosan. This makes boronated 
derivatives of chitosan promising as mucoadhesive excipients for formulating dosage forms not 
only for intravesical drug delivery but also for applications in other mucosal routes of drug 
administration.  
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